Tag Archives: R&D
By William Looney | Published: February 28, 2014
R&D’s Double Header The Myelin Repair Foundation is more than just a policy precedent – it’s also emerging as the stimulus behind a future cure for MS. The decades-old movement for “patient power” is evolving in unexpected directions, as a few vanguard organizations explicitly abandon that vague agenda around “advocacy” for something more granular and […]
By Julian Upton | Published: February 26, 2014
Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.
By Guest Blogger | Published: February 24, 2014
Risk-Based Monitoring: From the Road Less Traveled to Productivity Superhighway By: Mukhtar Ahmed, global vice president, life sciences strategy, Oracle Health Sciences The latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups. Clinical trials cost 60% more today than they did just […]
By Guest Blogger | Published: February 18, 2014
America’s biopharmaceutical research companies are currently developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development, all either in clinical trials or under review by FDA, include 30 for type 1 diabetes, 100 for type 2, and 52 for diabetes-related conditions, according to a new report […]
By Guest Blogger | Published: February 12, 2014
By Moe Alsumidaie. The clinical trial technological landscape continues to morph, as we are starting to see the emergence of novel technologies and techniques to enhance clinical trial strategies and productivity. Study site/enrollment optimization, patient engagement, and big data were hot topics at this year’s SCOPE Summit in Miami, FL, last week.